Abevmy 400 Vial — Bevacizumab 400 mg/16 ml (1 Vial) Mylan

Abevmy is prescribed by an oncologist (either alone or with chemotherapy) for the treatment of:

• 🔹 Metastatic colorectal cancer.
• 🔹 Non-small cell lung cancer (NSCLC) — advanced, metastatic, or recurrent.
• 🔹 Metastatic renal cell carcinoma (kidney cancer).
• 🔹 Ovarian, fallopian tube, or primary peritoneal cancer.
• 🔹 Cervical cancer (persistent, recurrent, or metastatic).
• 🔹 Recurrent glioblastoma (brain tumor).

Sales Unit: 1 single-use glass vial containing 400 mg of bevacizumab in 16 ml. Concentrate for solution for intravenous (I.V.) infusion.

⚠️ APPLICATION INSTRUCTIONS:

• Method: For intravenous infusion (drip) only. It must NOT be administered as an intravenous push or bolus.
• Dosage: Strictly individualized based on body weight (typically 5 mg to 15 mg per kg) and the clinical protocol.
• Frequency: Administered usually once every 2 or 3 weeks.
• Storage: Keep in the original carton to protect from light, stored in a refrigerator (2-8°C).

• ⛔ Surgery: Do not start treatment for at least 28 days following major surgery or until the wound is fully healed.
• ⛔ Bleeding: Active severe hemorrhage or recent hemoptysis (coughing up blood).
• Pregnancy and breastfeeding (highly hazardous to the fetus).
• Hypersensitivity to bevacizumab or any excipients.
• Children and adolescents (safety not established).

Treatment requires professional medical supervision. Potential side effects include:

• 🫀 Vascular: High blood pressure (hypertension) — requires regular monitoring.
• 🩸 Hematologic: Nosebleeds, low white blood cell count (neutropenia).
• 🟡 Renal: Protein in the urine (proteinuria).
• ⚠️ General: Impaired wound healing, risk of GI perforation (rare), fatigue.